JPRN-UMIN000018740Completed未知
Effects of exenatide extended-release in patients with type 2 diabetes mellitus - Effects of exenatidein patients with type 2 diabetes mellitus
Tokyo Women's Medical University0 sites100 target enrollmentStarted: August 21, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •- patients contraindicated to the study drugs - patients treated with insulin - patients with uncontrollable hypertension - pregnant women or women who are possibly pregnant
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Effect of additional treatment with exenatide in patients with an acute myocardial infarction: the EXAMI trial)EUCTR2009-014272-21-NLVU University Medical Center40
Completed
Phase 2
Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI trial10019280Acute myocardial infarctionNL-OMON40038Vrije Universiteit Medisch Centrum125
Recruiting
Phase 3
The effects of exenatide extended release ( Bydureon) on appetite and gastric emptying in Prader-Willi syndromePrader-Willi syndromeMetabolic and Endocrine - Other endocrine disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersNeurological - Other neurological disordersACTRN12616000710426Garvan Institute of Medical Research40
Recruiting
Not Applicable
Comparison of efficacy and safety of exenatide extended-release and dulaglutide in type 2 diabetes mellitus patients who are insufficiently controlled with oral antidiabetic agentsType 2 diabetes mellitusJPRN-UMIN000019096Haga Diabetes Clinic75
Active, not recruiting
Not Applicable
Prediction of the efficacy of exenatide treatment in suboptimally controlled type 2 diabetic patients by Metabolic Fingerprint” and evidence-based KADIS® decision support: a clinical pilot trial - KADIS-Byettathe trial will be performed in a total of 58 male and female patients with type 2 diabetes who will be assigned to two groups, receiving either exenatide or insulin glargineEUCTR2008-006251-46-DEInstitute of Diabetes Gerhardt Katsch”72